Présentation de l'entreprise
Park Ha Biological Technology Co., Ltd. operates as an investment holding company dedicated to the development of skincare products within the People's Republic of China, serving both domestic and potentially international markets through its specialized product lines. The firm is categorized within the Consumer Defensive sector, specifically the Household & Personal Products industry, a classification that typically implies exposure to non-discretionary consumer demand for personal care items, although its specific market positioning must be evaluated against these broad definitions. In terms of scale, the company reports a market capitalization of $3.45M and generates annual revenue of $2.52M over the trailing twelve-month period, employing a workforce of 41 individuals to execute its operations. These financial dimensions indicate a small-cap entity with limited revenue generation relative to its market valuation metrics, suggesting the company is in a niche or early-stage growth phase where operational leverage has not yet been fully realized.
Santé financière
The company's financial performance over the trailing twelve months shows revenue of $2.52M, yet this figure contrasts sharply with a net income of $-24,364,752, revealing a significant divergence that highlights an aggressive or unsustainable cost structure where expenses far exceed gross profitability. This discrepancy is further evidenced by an EBITDA of $-24,039,532, indicating that the business is currently burning cash at a substantial rate before accounting for interest and taxes. While the gross margin stands at an impressive 94.4%, the operating margin is negative at -344.8% and the profit margin is 0.0%, suggesting that while production costs are low relative to sales, overheads, R&D, or administrative expenses are consuming all operating profit, resulting in a loss on every dollar of profit. The company holds $3.79M in cash against a total debt obligation of $180,169, creating a net cash position, yet the debt-to-equity ratio is reported as 4.51, a metric that, combined with negative equity returns, suggests a complex capital structure rather than traditional leverage. Liquidity is supported by a current ratio of 2.92, which indicates a robust ability to meet short-term obligations with its current assets, providing a buffer against immediate financial distress despite operational losses. Return on Equity is -885.8% and Return on Assets is -334.1%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Évaluation de la valorisation
Valuation multiples for Park Ha Biological Technology Co., Ltd. present a mixed picture due to the absence of traditional earnings-based metrics, as both the trailing P/E and forward P/E are N/A, reflecting the company's negative earnings which preclude the calculation of these standard ratios and imply that any future earnings growth would be required to justify a multiple. The price-to-book ratio is 0.18, indicating that the market is valuing the company at significantly less than its book value, which often suggests a deep discount or potential undervaluation if assets are liquid, though it can also signal fundamental distress. Alternative valuation metrics such as the price-to-sales ratio of 1.36 and an EV/EBITDA of 0.12 provide insight into the company's pricing relative to its top-line revenue and enterprise value, showing a valuation that is low relative to sales but heavily influenced by the negative earnings profile. The stock trades between a 52-week high of $2074.50 and a 52-week low of $0.93, a range that suggests extreme price volatility and potential issues with price discovery or delisting risks given the proximity of the current price to the lower bound. The beta is N/A, meaning that the stock's volatility relative to the broader market cannot be quantified with this standard metric, likely due to low liquidity or data limitations associated with the company's small market cap.
Growth & Income
Revenue growth year-over-year stands at -15.9%, while earnings growth is N/A due to negative earnings, indicating that the company is contracting in terms of sales rather than expanding its revenue base, which is a critical concern for a business in the consumer defensive sector. The earnings growth rate cannot be calculated meaningfully in the traditional sense, but the trajectory of revenue decline suggests that the company is losing market share or facing significant headwinds that are outpacing any potential internal efficiency gains. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings are theoretically available for reinvestment but are currently being consumed by losses rather than funding growth initiatives. Consequently, the overall growth and income profile is characterized by negative revenue expansion and a lack of income distribution, relying entirely on the potential for a turnaround in operations to restore profitability and cash flow generation in the future.